News | January 30, 2026
Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
NewCo’s pipeline includes five investigational medicines
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
25 women students to receive internship, training, and mentorship in Life Sciences segment
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
